OCM
BTAI icon

Ovata Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Ovata Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-313
Closed -$231K – 49
2020
Q4 		$231K Sell
313
-312
-50% -$243K 0.07% 42
2020
Q3 		$434K Buy
+625
New +$469K 0.15% 44

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ovata Capital Management's BTAI Position: Q1 2021 in Review

Ovata Capital Management sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 313 shares — an estimated $231K sold.

Ovata Capital Management first reported a position in BTAI in Q3 2020 and held it in 2 quarters. The position peaked at $434K in Q3 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

  • Ovata Capital Management reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Ovata Capital Management sold 313 BioXcel Therapeutics shares in Q1 2021, an estimated $231K.
  • Ovata Capital Management first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 2 quarters.
  • Ovata Capital Management's BioXcel Therapeutics position peaked at $434K in Q3 2020.
  • 116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on Ovata Capital Management's 13F filing for Q1 2021, filed 17 May 2021.